Chemotherapy Response Evaluation in Metastatic Colorectal Cancer with FDG PET/CT and CT Scans

• Published in: Anticancer research Vol. 29; no. 7; pp. 2563 - 2568
• Main Authors: J. MONTEIL, N. MAHMOUDI, S. LEOBON, P.Y. ROUDAUT, A. EL BADAOUI, S. VERBEKE, L. VENAT-BOUVET, J. MARTIN, V. LE BRUN-LY, S. LAVAU-DENES, A. MAUBON, P. BOUILLET, M. POUQUET, J.C. VANDROUX, N. TUBIANA-MATHIEU
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01.07.2009
• Subjects: Adult; Aged; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Colorectal Neoplasms - diagnostic imaging; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - pathology; Female; Fluorodeoxyglucose F18; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Male; Medical sciences; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Tomography, X-Ray Computed; Tumors; Radionuclide study; 2-deoxy-2-fluoroglucose; Rectal disease; Radiodiagnosis; [18F]-FDG; Colorectal cancer; PET-CT; Malignant tumor; Metastasis; therapeutic assessment; Colonic disease; Chemotherapy; Treatment; Cancerology; Medical imagery; Digestive diseases; Intestinal disease; Advanced stage; metastatic colorectal cancer; Computerized axial tomography; Positron emission tomography; CT scan; Cancer
• ISSN: 0250-7005; 1791-7530

Background: [18F]-fluorodeoxyglucose with positron-emission tomography (PET) and computed tomography (CT) scans were used to assess morphological and metabolic tumour response after chemotherapy in metastatic colorectal cancer. Patients and Methods: Twenty-five patients were evaluated after 4 courses of chemotherapy (±target therapy), and among them 20 patients after 2 courses. Response Evaluation Criteria In Solid Tumors (RECIST) and European Organisazion for Research and Treatment of Cancer (EORTC) criteria were used to evaluate CT and PET respectively. Results: Discrepancies between the two procedures were noted after 4 courses of chemotherapy in patient-based analysis. Two morphologically complete responses (CR) were correlated with metabolic response. Seven morphological partial responses (PR) were evaluated as 3 metabolic PR, 2 CR and 1 progressive disease (PD). Seventeen cases of morphologically stable disease (SD) were evaluated as 3 metabolic CR, 13 PR and 1 PD. These discrepancies were confirmed in lesion-based analysis. Perfect concordance was noted between metabolic responses obtained after 2 and 4 cycles. Conclusion: Morphological and metabolic imaging does not permit concordant therapeutic assessment in metastatic colorectal cancer.